凯赛生物: 2024年年度股东大会法律意见书

Core Viewpoint - The legal opinion letter from Shanghai Jintiancheng Law Firm confirms the legality and validity of the procedures and results of the 2024 annual general meeting of Shanghai Kaisa Biotechnology Co., Ltd. [1][12] Group 1: Meeting Procedures - The annual general meeting was proposed and convened by the board of directors, with the notice published on June 5, 2025 [4][6] - The meeting was held on June 27, 2025, using a combination of on-site and online voting methods [4][6] - The meeting was presided over by the chairman of the company, Liu Xiucai [4] Group 2: Attendance and Voting - A total of 183 shareholders and representatives attended the meeting, representing 426,988,631 shares, which is 59.39% of the total voting shares [5][6] - The meeting included 24 on-site attendees and 159 online voters, with the online voting system verifying shareholder qualifications [5][6] - The legal opinion confirms that all attendees had valid qualifications according to relevant laws and regulations [6] Group 3: Proposals and Voting Results - The meeting reviewed a total of 9 proposals, with specific proposals (4, 7, 8) counted separately for small and medium investors [8][11] - Voting results showed significant support for the proposals, with the majority of votes in favor, including 426,785,801 shares for one of the proposals [9][10] - The legal opinion asserts that the voting procedures and results were in compliance with legal and regulatory requirements [12]